• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
  

PubMed=1358431
Masayuki Nakagawa, Erasmus Schneider, Katharine H. Dixon, Julie K. Horton, Kristin Kelley, Charles S. Morrow, Kenneth H. Cowan;
Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells.
Cancer Res. 52:6175-6181(1992)

PubMed=7664272
Chih-Hsin J. Yang, Julie K. Horton, Kenneth H. Cowan, Erasmus Schneider;
Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
Cancer Res. 55:4004-4009(1995)

PubMed=9865745
Sridhar K. Rabindran, Hai-Yin He, Maya Singh, Eileen Brown, Karen I. Collins, Tami Annable, Lee M. Greenberger;
Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C.
Cancer Res. 58:5850-5858(1998)

PubMed=11559526
Yasumasa Honjo, Christine A. Hrycyna, Qing-Wu Yan, Wilma Y. Medina-Perez, Robert W. Robey, Anne van de Laar, Thomas Litman, Michael Dean, Susan E. Bates;
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
Cancer Res. 61:6635-6639(2001)